We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial.
- Authors
Gabriel, Rafael; Boukichou-Abdelkader, Nisa; Gilis-Januszewska, Aleksandra; Makrilakis, Konstantinos; Gómez-Huelgas, Ricardo; Kamenov, Zdravko; Paulweber, Bernhard; Satman, Ilhan; Djordjevic, Predrag; Alkandari, Abdullah; Mitrakou, Asimina; Lalic, Nebojsa; Egido, Jesús; Más-Fontao, Sebastián; Calvet, Jean Henri; Pastor, José Carlos; Lindström, Jaana; Lind, Marcus; Acosta, Tania; Silva, Luis
- Abstract
Objective: To compare the effect of glucose-lowering drugs on peripheral nerve and kidney function in prediabetes. Methods: Multicenter, randomized, placebo-controlled trial in 658 adults with prediabetes treated for 1 year with metformin, linagliptin, their combination or placebo. Endpoints are small fiber peripheral neuropathy (SFPN) risk estimated by foot electrochemical skin conductance (FESC < 70 μSiemens) and estimated glomerular filtration rate (eGFR). Results: Compared to the placebo, the proportion of SFPN was reduced by 25.1% (95% CI:16.3–33.9) with metformin alone, by 17.3% (95% CI 7.4–27.2) with linagliptin alone, and by 19.5% (95% CI 10.1–29.0) with the combination linagliptin/metformin (p < 0.0001 for all comparisons). eGFR remained +3.3 mL/min (95% CI: 0.38–6.22) higher with the combination linagliptin/metformin than with the placebo (p = 0.03). Fasting plasma glucose (FPG) decreased more with metformin monotherapy −0.3 mmol/L (95%CI: −0.48; 0.12, p = 0.0009) and with the combination metformin/linagliptin −0.2 mmol/L (95% CI: −0.37; −0.03) than with the placebo (p = 0.0219). Body weight (BW) decreased by −2.0 kg (95% CI: −5.65; −1.65, p = 0.0006) with metformin monotherapy, and by −1.9 kg (95% CI: −3.02; −0.97) with the combination metformin/linagliptin as compared to the placebo (p = 0.0002). Conclusions: in people with prediabetes, a 1 year treatment with metformin and linagliptin, combined or in monotherapy, was associated with a lower risk of SFPN, and with a lower decrease in eGFR, than treatment with placebo.
- Subjects
SIEMENS AG; PERIPHERAL neuropathy; KIDNEY physiology; RANDOMIZED controlled trials; METFORMIN; LINAGLIPTIN
- Publication
Journal of Clinical Medicine, 2023, Vol 12, Issue 5, p2035
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm12052035